Siemens Fonds Invest GmbH increased its position in shares of Henry Schein, Inc. (NASDAQ:HSIC - Free Report) by 282.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 13,366 shares of the company's stock after buying an additional 9,870 shares during the quarter. Siemens Fonds Invest GmbH's holdings in Henry Schein were worth $925,000 as of its most recent SEC filing.
Other hedge funds have also modified their holdings of the company. Private Management Group Inc. grew its stake in Henry Schein by 5.7% in the fourth quarter. Private Management Group Inc. now owns 350,515 shares of the company's stock valued at $24,256,000 after purchasing an additional 18,882 shares in the last quarter. Equitable Trust Co. bought a new position in Henry Schein in the fourth quarter valued at approximately $417,000. Savant Capital LLC grew its stake in Henry Schein by 43.9% in the fourth quarter. Savant Capital LLC now owns 4,651 shares of the company's stock valued at $322,000 after purchasing an additional 1,420 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in Henry Schein by 29.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 15,854 shares of the company's stock valued at $1,113,000 after purchasing an additional 3,650 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in Henry Schein by 1.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,191,677 shares of the company's stock valued at $82,464,000 after purchasing an additional 16,616 shares in the last quarter. 96.62% of the stock is currently owned by institutional investors.
Insider Buying and Selling at Henry Schein
In related news, Director Philip A. Laskawy sold 2,604 shares of the business's stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $71.04, for a total transaction of $184,988.16. Following the sale, the director now owns 24,805 shares in the company, valued at $1,762,147.20. The trade was a 9.50% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Bradford C. Connett sold 4,036 shares of the business's stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $71.15, for a total value of $287,161.40. Following the sale, the chief executive officer now owns 62,688 shares in the company, valued at $4,460,251.20. This represents a 6.05% decrease in their position. The disclosure for this sale can be found here. Insiders own 1.08% of the company's stock.
Wall Street Analyst Weigh In
A number of research analysts have weighed in on the company. Piper Sandler decreased their price target on Henry Schein from $83.00 to $77.00 and set an "overweight" rating for the company in a research note on Wednesday, April 30th. Barrington Research decreased their price target on Henry Schein from $90.00 to $86.00 and set an "outperform" rating for the company in a research note on Tuesday, May 6th. Wall Street Zen downgraded Henry Schein from a "buy" rating to a "hold" rating in a research note on Thursday, April 17th. UBS Group decreased their price target on Henry Schein from $83.00 to $80.00 and set a "neutral" rating for the company in a research note on Wednesday, February 26th. Finally, Wells Fargo & Company cut their price objective on Henry Schein from $80.00 to $75.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. Six investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $79.30.
Read Our Latest Stock Analysis on Henry Schein
Henry Schein Stock Performance
NASDAQ:HSIC traded down $0.43 during mid-day trading on Monday, hitting $69.56. 2,497,178 shares of the stock were exchanged, compared to its average volume of 1,675,450. The stock has a market capitalization of $8.47 billion, a price-to-earnings ratio of 28.63, a price-to-earnings-growth ratio of 2.13 and a beta of 0.87. The firm's 50-day simple moving average is $67.65 and its 200 day simple moving average is $71.70. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.82 and a current ratio of 1.42. Henry Schein, Inc. has a fifty-two week low of $60.56 and a fifty-two week high of $82.49.
Henry Schein (NASDAQ:HSIC - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.11 by $0.04. The business had revenue of $3.17 billion during the quarter, compared to analysts' expectations of $3.24 billion. Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The firm's revenue for the quarter was down .1% compared to the same quarter last year. During the same period last year, the firm posted $1.10 EPS. As a group, equities analysts anticipate that Henry Schein, Inc. will post 4.74 EPS for the current fiscal year.
Henry Schein Profile
(
Free Report)
Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Featured Articles

Before you consider Henry Schein, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Henry Schein wasn't on the list.
While Henry Schein currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.